Jardiance (Empagliflozin) Pediatric Monitoring: What Clinicians Need to Know for Children Under 12

Is Empagliflozin FDA-Approved for Children Under 12?

Empagliflozin received expanded FDA approval in December 2023 for type 2 diabetes in patients aged 10 and older, making children under 10 strictly off-label territory. The approval was based on pharmacokinetic bridging data and the pediatric extrapolation framework supported by the FDA's Pediatric Research Equity Act. No adequately powered randomized controlled trial has yet evaluated empagliflozin exclusively in children under 10 with type 2 diabetes.

The FDA labeling specifies that dosing and safety data do not extend to patients under age 10, and the Prescribing Information explicitly states that safety and efficacy in pediatric patients below that threshold have not been established [1]. Clinicians who prescribe empagliflozin to children under 10 bear full responsibility for informed-consent documentation, close monitoring, and institutional review when applicable.

Children between 10 and 11 years of age fall within the approved label but still occupy the youngest end of the studied population. The American Diabetes Association's 2024 Standards of Care in Diabetes notes that pharmacotherapy selection in youth-onset type 2 diabetes should account for pubertal status, body weight trajectory, and renal maturation, all of which vary considerably in this age window [2].

Understanding the Pharmacokinetics of Empagliflozin in Young Children

Renal tubular development continues through early childhood and is largely complete by age 2, yet glomerular filtration rates normalized to body surface area do not consistently reach adult values until approximately age 12 [3]. This matters because empagliflozin works by inhibiting sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule. Lower absolute GFR in a small child means less drug is filtered and less glucose is excreted per dose.

Population pharmacokinetic modeling submitted to the FDA showed that a 5 mg once-daily dose in children aged 10 to 17 produced exposures comparable to those seen with 10 mg in adults, supporting the lower starting dose in the pediatric label [1]. No published PK data exist for children under 8 years of age. This gap matters clinically.

Renal clearance of empagliflozin itself is approximately 11.4 mL/min in adult studies, and protein binding is roughly 86% [4]. In very young children with lower plasma protein concentrations, free-drug fraction could theoretically be higher, though this has not been studied in ages under 10. Prescribers should use the lowest available dose and monitor renal function closely from the first week onward.

Baseline Monitoring Before Starting Empagliflozin in a Child

Before initiating empagliflozin in any pediatric patient, a structured baseline evaluation is not optional. The minimum required workup includes:

• A complete metabolic panel to establish serum creatinine, electrolytes, bicarbonate, and BUN.
• Estimated GFR calculated using the CKiD U25 equation, which is more accurate than the CKD-EPI formula for children [5].
• Urinalysis with microscopy to rule out active urinary tract infection, which is a contraindication to starting therapy.
• Urine albumin-to-creatinine ratio (UACR) as a baseline nephrology marker.
• HbA1c and fasting glucose to confirm the diagnosis and establish a treatment benchmark.
• Height, weight, and BMI plotted on CDC pediatric growth charts [6].
• Blood pressure measurement, since empagliflozin produces a modest osmotic diuresis that may affect blood pressure in volume-sensitive children.

The FDA Prescribing Information for Jardiance lists eGFR <30 mL/min/1.73 m² as a contraindication for glycemic control in adults; in pediatric practice, most pediatric endocrinologists apply the more conservative threshold of <45 mL/min/1.73 m² before initiation, consistent with the 2022 KDIGO guideline recommendations for SGLT2 inhibitor use in CKD [7].

How to Monitor Renal Function During Empagliflozin Therapy

Empagliflozin causes a small, predictable, and reversible decline in eGFR during the first 4 to 6 weeks of treatment. This is a hemodynamic effect of reduced tubuloglomerular feedback, not structural nephron loss. In the EMPA-REG OUTCOME trial (N=7,020 adults with type 2 diabetes and established cardiovascular disease), eGFR dipped by roughly 4 mL/min/1.73 m² in the first 4 weeks then stabilized, while the placebo group showed a slow linear decline over 3.1 years of follow-up [8]. That trial remains the cornerstone of empagliflozin's cardiorenal evidence base, even though its population was adult.

For pediatric patients, the recommended renal monitoring schedule is:

1. Recheck BMP and eGFR at 4 weeks after initiation.
2. Repeat every 3 months for the first year.
3. After the first year, every 6 months if eGFR remains stable above 60 mL/min/1.73 m².
4. Suspend empagliflozin temporarily if eGFR drops below 45 mL/min/1.73 m² or if the child is acutely ill with vomiting, diarrhea, or reduced oral intake.

The 2022 KDIGO Diabetes Management in CKD guideline states directly: "We recommend treatment with an SGLT2 inhibitor in patients with type 2 diabetes and CKD who have an eGFR ≥20 mL/min/1.73 m²," but also notes that the evidence base in pediatric CKD is insufficient and that individualized clinical judgment is required [7]. Pediatric nephrologists should be involved whenever a child with pre-existing renal disease is considered for SGLT2 inhibitor therapy.

Diabetic Ketoacidosis Risk: The Most Serious Monitoring Priority

Euglycemic DKA is the most dangerous acute complication associated with SGLT2 inhibitors, and the risk profile in children differs from adults in ways that deserve explicit attention. Children with type 2 diabetes frequently have underlying insulin deficiency that is more severe than in adult-onset type 2 diabetes, narrowing the biochemical margin before ketogenesis accelerates [9].

The FDA issued a Drug Safety Communication in 2015 warning about DKA with SGLT2 inhibitors [10]. A subsequent 2020 FDA label update reinforced that DKA may occur with blood glucose levels that are only mildly elevated or even within the normal range, making it easy to miss in a child presenting with nausea and fatigue.

Situations that substantially raise DKA risk in children on empagliflozin include:

• Perioperative fasting. Hold empagliflozin at least 3 days before any elective procedure requiring general anesthesia, consistent with guidance from the Society for Pediatric Anesthesia [11].
• Intercurrent illness with reduced carbohydrate intake.
• Prolonged vigorous exercise without adequate carbohydrate replacement.
• Concomitant insulin dose reduction without endocrinologist guidance.

Caregivers should be taught to check urine or blood ketones any time a child on empagliflozin vomits more than once, feels unusually tired, or has abdominal pain, regardless of blood glucose reading. A point-of-care blood beta-hydroxybutyrate above 1.5 mmol/L in a symptomatic child warrants immediate ED evaluation.

Urinary and Genital Infection Monitoring

The glucosuria produced by SGLT2 inhibition creates a sugar-rich urine environment that promotes fungal and bacterial growth. In adult trials, genital mycotic infections occurred in roughly 6% to 10% of women taking empagliflozin versus 1% to 3% on placebo [12]. Pediatric-specific incidence data are sparse, but mechanistically the risk is analogous.

Girls aged 10 to 11 who are not yet fully estrogenized have vaginal epithelium that is more susceptible to Candida colonization. Clinicians should ask about vaginal discharge, pruritus, and dysuria at every follow-up visit. Oral fluconazole at weight-appropriate dosing (3 mg/kg, maximum 150 mg, single dose) is the standard first-line treatment for vulvovaginal candidiasis in prepubertal and early pubertal girls [13].

Uncomplicated urinary tract infections should be treated with a standard antibiotic course, and empagliflozin may be continued unless the child is febrile, suggesting upper tract involvement. Pyelonephritis requires temporary drug suspension and IV antibiotics when the child cannot tolerate oral intake.

Fournier gangrene, a necrotizing fasciitis of the perineum, is extremely rare but has been reported with all SGLT2 inhibitors. The FDA added a Boxed Warning update in 2018 [14]. Caregivers should be told to seek emergency care immediately if a child develops pain, redness, or swelling in the genital or perineal area, especially with fever.

Growth and Development Monitoring

No pediatric SGLT2 inhibitor trial has been long enough to detect meaningful effects on linear growth or pubertal timing, but the physiologic basis for concern exists. Empagliflozin reduces caloric absorption by excreting 60 to 90 grams of glucose per day in adults taking 10 mg [15]. The equivalent caloric deficit in a 35 kg child could represent 3% to 5% of daily caloric needs if dietary intake is not adjusted upward.

Every clinical visit should include:

• Height plotted on CDC growth charts [6]. A drop of more than one percentile channel over 6 months warrants dietary review and possible dietitian referral.
• Weight and BMI. Modest weight reduction is expected and generally favorable in pediatric type 2 diabetes, but excessive loss (more than 2 standard deviations from baseline trajectory over 3 months) requires reassessment.
• Pubertal staging using Tanner scale documentation at least every 6 months, since insulin resistance and sex hormone levels interact in ways that affect drug responsiveness.
• Bone health assessment annually in any child with additional fracture risk factors, since SGLT2 inhibitors have been associated with modest decreases in bone mineral density in adult studies [16].

Adequate calcium and vitamin D intake should be confirmed at baseline and reinforced at every visit, particularly for children with obesity-related low vitamin D, which is common in pediatric type 2 diabetes [2].

HbA1c and Glycemic Monitoring Schedule

The ADA 2024 Standards of Care recommend an HbA1c target of <7.0% for most children and adolescents with type 2 diabetes who can achieve it without excessive hypoglycemia [2]. Empagliflozin as monotherapy or add-on therapy produces HbA1c reductions of approximately 0.5% to 0.8% in adults at the 10 mg dose [17]. Pediatric extrapolation suggests comparable or slightly larger reductions given higher baseline HbA1c values typical of youth-onset type 2 diabetes.

HbA1c should be checked:

• At baseline.
• At 3 months after initiation to assess initial response.
• Every 3 months until the target is reached and stable.
• Every 6 months once HbA1c is stable below 7.0%.

Continuous glucose monitoring is preferred over fingerstick HbA1c alone for children, since HbA1c can be falsely low in those with sickle cell trait or hemolytic conditions, both of which are more prevalent in the populations disproportionately affected by youth-onset type 2 diabetes [2]. Time in range (70 to 180 mg/dL) above 70% and time below range below 4% are the CGM targets endorsed by the 2023 International Consensus on Time in Range [18].

Volume and Blood Pressure Monitoring

The osmotic diuretic effect of empagliflozin is generally mild in adults, but children have smaller total body water reserves and may be more susceptible to dehydration. Orthostatic symptoms, decreased urine output, or dry mucous membranes during the first 2 weeks of therapy should prompt a recheck visit.

Baseline blood pressure should be recorded with an appropriately sized pediatric cuff. In children with normal or low blood pressure at baseline, the modest BP-lowering effect seen in adults (roughly 3 to 4 mmHg systolic in EMPA-REG OUTCOME [8]) is generally not clinically significant, but warrants documentation. Children already receiving antihypertensives or diuretics need more frequent blood pressure checks in the first month.

A serum sodium and potassium check at the 4-week visit is reasonable for any child also receiving a loop diuretic, ACE inhibitor, or ARB, since combined volume depletion and renin-angiotensin-aldosterone system blockade can precipitate electrolyte disturbances.

Drug Interactions and Concomitant Medication Review

Empagliflozin has a relatively clean drug interaction profile because it is primarily metabolized by UGT1A3 and UGT2B7 glucuronosyltransferases rather than CYP450 enzymes [4]. However, several interactions matter in pediatric practice:

• Insulin and insulin secretagogues (sulfonylureas): The combination increases hypoglycemia risk. If a child is on both, the insulin or secretagogue dose may need reduction when empagliflozin is added.
• Rifampicin and other potent UGT inducers: These reduce empagliflozin exposure by roughly 35%, potentially blunting glycemic efficacy [4].
• Loop diuretics: Combined diuresis may cause volume depletion, particularly in children with heart failure or nephrotic syndrome.
• NSAIDs: Chronic NSAID use impairs renal prostaglandin synthesis, potentially amplifying the hemodynamic GFR dip from SGLT2 inhibition [19].

A full medication reconciliation, including over-the-counter products and supplements, should be performed at every visit.

Monitoring Framework Summary: A Visit-by-Visit Schedule for Empagliflozin in Children Under 12

The table below consolidates the monitoring schedule described throughout this article. This framework is intended for clinical teams managing pediatric patients aged 10 to 11 on empagliflozin, or younger children receiving off-label therapy under specialist supervision.

Baseline (before first dose)

• BMP, eGFR (CKiD U25), urinalysis, UACR, HbA1c, fasting glucose
• Height, weight, BMI on CDC growth charts
• Blood pressure (pediatric cuff)
• Tanner staging
• Medication reconciliation
• DKA risk counseling for caregivers

Week 4

• BMP, eGFR recheck
• Blood pressure
• Symptom review: volume depletion, genital/urinary symptoms, ketone symptoms
• Weight

Month 3

• HbA1c
• BMP, eGFR
• UACR
• Height, weight, BMI
• Tanner staging
• Review DKA sick-day rules

Every 3 months (first year)

• HbA1c, BMP, eGFR
• Weight, height plotted
• Symptom screen for infections and volume depletion

Every 6 months (after first year, if stable)

• HbA1c, BMP, eGFR, UACR
• Growth parameters and Tanner staging
• Annual bone health assessment if additional fracture risk factors are present
• Vitamin D and calcium intake review

When to Discontinue or Temporarily Hold Empagliflozin

Temporary holds are appropriate in the following situations, and caregivers should receive a written sick-day plan at initiation:

• eGFR falls below 45 mL/min/1.73 m² on repeat testing.
• Acute illness with vomiting, diarrhea, or inability to tolerate oral fluids.
• Planned surgery or procedure requiring general anesthesia or prolonged fasting (hold at least 3 days prior) [11].
• Blood or urine ketones are elevated above the threshold for outpatient management.
• Suspected or confirmed urinary tract infection with systemic features (fever, flank pain).

Permanent discontinuation is warranted if:

• eGFR consistently falls below 30 mL/min/1.73 m² for glycemic indications.
• Recurrent DKA events occur while on therapy.
• Fournier gangrene is diagnosed.
• The child develops a serious adverse drug reaction attributed to empagliflozin after specialist review.

The 2024 ADA Standards of Care specify that SGLT2 inhibitors should be discontinued at hospital admission and restarted only after the child has resumed normal oral intake and renal function has been confirmed stable [2].